ResMed Inc. (RMD)
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed (RMD) Upgraded to Buy: Here's Why
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point
ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% share in a vast, under-penetrated addressable market with huge future growth potential. RMD's financials are resilient, with consistent sales and earnings growth, no earnings misses in more than a decade, and a predictable business model.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed: GLP-1 Threats Are Overstated
My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Hidden 401(k) Tax Bomb That Hits a $1.3 Million Saver With $19,800 in Their First RMD Year
Picture a single 73-year-old retiree sitting on $1.3 million in a traditional 401(k), drawing $36,000 a year in Social Security, and feeling reasonably set for retirement.
